

Diagnosis:

Medication name

If yes, please indicate date:_

Start date

MedStar Medicare Choice **Pharmacy Services** Phone: 855-266-0712

Specialty:

Reason for Failure or

Discontinuation

Revised: 10/2016

Fax: 855-862-6517

GILENYA Prior Authorization Form If you or your prescriber believe that waiting 72 hours for a standard decision could seriously harm your life, □ Standard Request (72 hours) health, or ability to regain maximum function, you can request an expedited decision. For expedited requests □ Expedited Request (24 hours) you will receive a decision within 24 hours. You cannot request an expedited coverage determination if you are requesting reimbursement for a drug you already received. **Demographics Patient Information Prescriber Information** Patient Name: Prescriber Name: DOB: NPI#:

Age:

End date

Health Plan ID#:				Pnone:		гах:	
Pharmacy Name:		Pharmacy Phon	ne:	Office Contact:		Direct Phone	e # or Ext:
		Medi	ication	Information			
Drug Requested:	Strength:	: D	irections	:	Quantity	Dispensed:	Day Supply:
Gilenva	0.5 mg						

Start Date: □ New medication If this is continuation of therapy, please provide CHART DOCUMENTATION Continuation of therapy indicating the member showed improvement while on therapy.

Please indicate past medication(s) tried and failed

Strength

Clinical Information Date of Diagnosis:

Frequency

☐ Avonex						
□ Copaxone						
□ Betaseron						
□ Extavia						
□ Rebif						
□ Tecfidera						
Does the member ha	ve a relapsing fo	rm of Multiple	Sclerosis?			□ Yes □ No
Will the member be o	bserved for 6 ho	ours for signs a	and symptoms of	f bradycardia?		□ Yes □ No
Does the member ha	ve evidence of a	ctive infection	?			□ Yes □ No
Did the member have If yes, please indica	,	the past 6 mg	onths) complete	blood count (CBC)?		□ Yes □ No
Did the member have	a recent (with i	n the past 6 m	onths) transamir	nase and bilirubin leve	l?	□ Yes □ No

Was the member vaccinated again If yes, please indicate date:	□ Yes □ No		
Has the member demonstrated implies If yes, please provide chart docu	☐ Yes ☐ No ☐ Chart Notes		
Did the member have a baseline o lf yes, please indicate date:	phthalmologic evaluation of the macula?		□ Yes □ No
Did the member have a recent election of the member has a recent election of	ctrocardiogram (ECG)?		□ Yes □ No
Does the member have Mobitz Typsick sinus syndrome? If yes, does the member have a feet of the	☐ Yes ☐ No ☐ Yes ☐ No		
Please provide the member's base	line QTc interval:		<u> </u>
If yes, please provide a spirometr diffusion lung capacity for carbon Did the member recently (in the pa angina, stroke, TIA, decompensate	g lung disease, such as asthma or COPD? ic evaluation of respiratory function and evamonoxide st 6 months) experience a myocardial infared heart failure requiring hospitalization, or	aluation of ction, unstable	☐ Yes ☐ No ☐ Chart Notes ☐ Yes ☐ No
	rapy with antineoplastic, immunosuppressiv	e therapy, or	□ Yes □ No
immune modulating therapies? If y	es, please complete below:		
	=	_	
Medication	Dose/Strength	Fr	equency
	-		equency
	Dose/Strength rapy with any Class I or Class III antiarrhyth		equency ☐ Yes ☐ No
Is the member on concomitant the	-	mic medications?	
Is the member on concomitant the If yes, please complete below:	rapy with any Class I or Class III antiarrhyth	mic medications?	☐ Yes ☐ No
Is the member on concomitant the If yes, please complete below: Medication Is this request for a reauthorizat If yes, please include the follow Documentation showing member's Documentation of no active infection Documentation of 3-month follow-use	rapy with any Class I or Class III antiarrhyth Dose/Strength ion? ving documentation: disease has improved and/or stabilized	Fr Yes No	☐ Yes ☐ No equency including date.
Is the member on concomitant the If yes, please complete below: Medication Is this request for a reauthorizat If yes, please include the follow Documentation showing member's Documentation of no active infection Documentation of 3-month follow-under the member Company of the member of	Dose/Strength ion? ving documentation: disease has improved and/or stabilized in p ophthalmologic evaluation within 3 to 4 month	Fr Yes No s of starting therapy, nonitored consistently	□ Yes □ No equency including date.
Is the member on concomitant the If yes, please complete below: Medication Is this request for a reauthorizat If yes, please include the follow Documentation showing member's Documentation of no active infection Documentation of 3-month follow-under the member Company of the member of	Dose/Strength Dose/Strength ion? ving documentation: disease has improved and/or stabilized on p ophthalmologic evaluation within 3 to 4 month BC and transaminase/bilirubin levels are being r	Fr Yes No s of starting therapy, nonitored consistently	□ Yes □ No equency including date.
Is the member on concomitant the If yes, please complete below: Medication Is this request for a reauthorizat If yes, please include the follow Documentation showing member's Documentation of no active infection Documentation of 3-month follow-under the member Company of the member of	Dose/Strength Dose/Strength ion? ving documentation: disease has improved and/or stabilized on p ophthalmologic evaluation within 3 to 4 month BC and transaminase/bilirubin levels are being r	Fr Yes No s of starting therapy, nonitored consistently	□ Yes □ No equency including date.
Is the member on concomitant the If yes, please complete below: Medication Is this request for a reauthorizat If yes, please include the follow Documentation showing member's Documentation of no active infection Documentation of 3-month follow-under the member Company of the member of	Dose/Strength Dose/Strength ion? ving documentation: disease has improved and/or stabilized on p ophthalmologic evaluation within 3 to 4 month BC and transaminase/bilirubin levels are being r	Fr Yes No s of starting therapy, nonitored consistently	□ Yes □ No equency including date.
Is the member on concomitant the If yes, please complete below: Medication Is this request for a reauthorizat If yes, please include the follow Documentation showing member's Documentation of no active infection Documentation of 3-month follow-under the member Company of the member of	Dose/Strength Dose/Strength ion? ving documentation: disease has improved and/or stabilized on p ophthalmologic evaluation within 3 to 4 month BC and transaminase/bilirubin levels are being r	Fr Yes No s of starting therapy, nonitored consistently	□ Yes □ No equency including date.

Revised: 10/2015